预约演示

J&J's Rybrevant combo bests AstraZeneca's established Tagrisso in key lung cancer study

2023-09-28

加速审批上市批准

J&J will present the study data and additional details on certain secondary endpoints at the upcoming European Society for Medical Oncology (ESMO) congress.

J&Jighly anticipated head-to-head matchup between a Johnson & Johnson combination and AstraZeneca’s star Tagrisso as a first-line treatment in a subset of non-small cell lung cancer (NSCLC) has yielded a winner.

In the MARIPOSA trial, J&J’s Rybrevant—combined withJohnson & Johnsonred lazertinib—heAstraZenecats with Tagrissoadvanced or metastatic epidermal growth fanon-small cell lung cancer (NSCLC) survive longer without disease progression compared with Tagrisso.

An interim analysis shoJ&J a Rybrevantavoring the combo oYuhanagrisso in lazertinibsion, J&J said in a Thursday press release. Investigators will growth factor receptord(EGFR)-mutated NSCLCoverall survival data.Tagrisso

The positive results “reinforce the potential of the RybrevanTagrissozertinib combinationJ&J frontline EGFR-mutated non-small cell lung cancer as a future standard of care," Janssen R&D’s oncology head, Peter Lebowitz, M.D., Ph.D., said in a statement.

J&J plans to present the study data at the upcoming ERybrevantocietlazertinibcal Oncology (ESMO) congreEGFR Janssen

J&Jan August note to clients, Leerink analysts pointed out that the peak sales potential for the combo will depend on the “magnitude of progression-free survival superiority” and overall survival results. The team noted that “the bar for MARIPOSA is high” because of Tagrisso’s “compelling” first-line commercial profile.

AZ recently reaffirmed its belLeerinkt Tagrisso can keep its standard-of-care designation in the first-line setting after a positive showing in a new chemotherapy combo at this year’s World Conference on Lung Cancer (WCLC) in Singapore.

That data in newly diagnosed EGFR-mutatTagrisso showcased the drug as a “valuable regimen for patients with higher tumor burden,” AZ’s oncology R&D chief Susan Galbraith, Ph.D. said in the company’s seconLung Cancerarnings call.

Rybrevant’s 2021 accelerated EGFRomutated NSCLChe first treatment to target NSCLC with EGFR exon 20 insertion mutattumorbefore Takeda’s Exkivity came along as a challenger. The two rivals split the U.S. market roughly 50-50 in the second-line setting, according to Takeda.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构